BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
Debruyne
F M
FM
Dep. of Urology, University Hospital, Nijmegen.
van der Meijden
A P
AP
Franssen
M P
MP
D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002291:Carcinoma, Papillary / Q000188:drug therapy / Q000601:surgery / Q000628:therapy; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000601:surgery / Q000628:therapy; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005060:Europe; D006801:Humans; D007322:Instillation, Drug; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D011897:Random Allocation; D001743:Urinary Bladder / Q000601:surgery; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*
D001500:BCG Vaccine; D008937:Mitomycins; D016685:Mitomycin